ICREA Academia
Fàtima Bosch i Turbet

Fàtima Bosch i Turbet

ICREA Academia 2012 & 2018

Universitat Autònoma de Barcelona · Life & Medical Sciences

Fàtima Bosch i Turbet

Fàtima Bosch is a Pharmacist (1980) and PhD in Biochemistry (1985) by the University of Barcelona. She conducted post-doctoral studies at Vanderbilt University (1985), Case Western Reserve University (1988-1990), and NCI-Frederick Cancer Research and Development Center (1991). She is currently Full Professor of Biochemistry and Molecular Biology (1999) and Director of the Center of Animal Biotechnology and Gene Therapy (2003) at the Universitat Autònoma Barcelona (UAB). She has been granted the Rey Juan Carlos I (1985), Francisco Grande Covián (1998), Narcís Monturiol (2002), Sant Jordi Cross (2005), Alberto Sols (2006) and ICREA Academia (2013-2017) awards. She has been Founding member of the European Society of Gene and Cell Therapy (1992), President of the Spanish Society of Gene and Cell Therapy (2007-2009), Vice-President of the European Association for the Study of Diabetes (2009-2012), member of the Gene Doping Expert Group of the World Anti-Doping Agency (2013-present).

Research interests

Prof. Bosch research focuses on studying the pathophysiological causes of diabetes mellitus using transgenic animal models and in developing gene therapy approaches for this disease by in vivo genetic manipulation of tissues using viral vectors. In recent years, she has also applied her know-how on gene transfer technologies to the development of gene therapies for severe inherited metabolic disorders such as Mucopolysaccharidosis (MPS). Since 2009, she is leading the UAB activities in the public-private partnership with the pharmaceutical company ESTEVE, established to develop gene therapies for the treatment of MPS. Presently, three gene therapy medicinal products have received the orphan drug designation by the European and North American authorities. The first clinical trial started in the first quarter of 2018, with a gene therapy for the treatment of MPSIIIA patients.


Gene Therapy, Diabetes, Mucopolysaccharidosis, Transgenic Animals